Hopewell Therapeutics Inc.
Hopewell Therapeutics is dedicated to advancing tissue-targeted lipid nanoparticle (ttLNP) technology to develop next-generation genomic medicines for patients with unmet medical needs. The company focuses on designing, synthesizing, and developing innovative lipid nanoparticles for targeted delivery of genomic medicines, including applications in oncology, infectious diseases, rare genetic diseases, and neurological disorders. With a strong scientific foundation from Tufts University and a robust intellectual property portfolio, Hopewell aims to overcome current drug delivery limitations and bring impactful therapies to patients.
Industries
Nr. of Employees
small (1-50)
Hopewell Therapeutics Inc.
Woburn, Massachusetts, United States, North America
Products
Internal preclinical LNP therapeutic candidates (lung-focused pipeline)
Internal development programs using tissue-targeted LNPs initially focused on pulmonary diseases, with exploratory programs in oncology, infectious disease, rare genetic and neurological disorders.
Internal preclinical LNP therapeutic candidates (lung-focused pipeline)
Internal development programs using tissue-targeted LNPs initially focused on pulmonary diseases, with exploratory programs in oncology, infectious disease, rare genetic and neurological disorders.
Services
Platform research and development collaborations
Collaborative R&D partnerships to apply tissue-targeted LNP technology for therapeutic programs, including joint preclinical studies and formulation optimization.
Analytical development services for mRNA‑LNP products
Development and execution of analytical workflows (HPLC/UPLC, LC–MS, lipid and RNA assays) and bioassays to support product characterization.
Platform research and development collaborations
Collaborative R&D partnerships to apply tissue-targeted LNP technology for therapeutic programs, including joint preclinical studies and formulation optimization.
Analytical development services for mRNA‑LNP products
Development and execution of analytical workflows (HPLC/UPLC, LC–MS, lipid and RNA assays) and bioassays to support product characterization.
Expertise Areas
- Lipid nanoparticle delivery platform development
- Ionizable lipid synthesis and formulation chemistry
- Nucleic acid therapeutic encapsulation (mRNA, siRNA, DNA, gene editing)
- Preclinical pharmacology, biodistribution and translational studies
Key Technologies
- Lipid nanoparticle formulation
- Ionizable lipid chemistry
- mRNA/siRNA/DNA encapsulation
- In vivo biodistribution studies in rodents and non-human primates